Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.
- Author:
Hyungseop KIM
1
;
Woo Baek CHUNG
;
Kyoung Im CHO
;
Bong Joon KIM
;
Jeong Sook SEO
;
Seong Mi PARK
;
Hak Jin KIM
;
Ju Hee LEE
;
Eun Kyoung KIM
;
Ho Joong YOUN
Author Information
- Publication Type:Review
- Keywords: Cardiovascular toxicity; Cardio-oncology; Anti-cancer treatment; Echocardiography
- MeSH: Biomarkers; Cardiotoxicity; Diagnosis*; Drug Therapy; Echocardiography*; Humans; Mortality; Risk Factors
- From:Journal of Cardiovascular Ultrasound 2018;26(1):1-25
- CountryRepublic of Korea
- Language:English
- Abstract: Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity. However, given the difficulty in determining a causal relationship, a multidisciplinary collaborative approach between cardiologists and oncologists is required. In this review, we summarize the CV toxicity and focus on the role of cardiac imaging in management strategies for cardiotoxicity associated with anti-cancer treatment.
